Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
DARE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.67 - $10.72
Previous CloseN/A
Volume4.87K
Average Volume (3M)29.06K
Market Cap
$25.06M
Enterprise Value$22.31M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 27, 2025EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding8,700,389
10 Day Avg. Volume17,127
30 Day Avg. Volume29,061
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.32
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.06
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$12.00Price Target Upside304.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Daré Bioscience News
PremiumCompany Announcements
Daré Bioscience to Present at BIO CEO Conference
PremiumCompany Announcements
Daré Bioscience Announces New Corporate Presentation
PremiumCompany Announcements
Daré Bioscience Advances Sildenafil Cream to Phase 3 Study
---
Bulls Say, Bears Say
Bulls Say
Funding And GrantsThe recent grant from the Gates foundation injected ~$11M into the Ovaprene program, allowing DARE to expand enrollment sites.
Product DevelopmentOvaprene is considered an exciting opportunity as it could be a blockbuster contraceptive device given the lack of convenient non-hormonal products on the market.
Strategic PartnershipsBayer may exercise its commercial option for Ovaprene after Phase 3 readout, potentially bringing in an additional $20M.
Bears Say
Financial ConstraintsRisks include financial because the company has capital needs greater than the company's current cash balance, and it is likely going to need to raise additional capital.
Regulatory And Development ChallengesSildenafil cream is intriguing but still needs FDA alignment, and there is uncertainty around the regulatory pathway.
Revenue Performance3Q24 revenue came in below the estimate of $3.1M and the Street consensus of $1M.
---
Ownership Overview
12.23%
Insiders
4.30% Mutual Funds
1.74% Other Institutional Investors
78.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $2.67 and its highest was $10.72 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is $25.06M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Mar 27, 2025 which is in 7 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Nov 14, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.685 by $0.135.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.53.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 8,700,389 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.685. Following the earnings report the stock price went down -9.831%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. (DARE) is a biopharmaceutical company focused on advancing innovative products for women's health. The company's portfolio addresses areas such as contraception, fertility, and sexual health. Daré Bioscience aims to improve the quality of life for women by developing therapies that fill unmet needs while providing convenience and effectiveness.
---
DARE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including substantial nondilutive funding, progress in product pipeline and clinical trials, and steady market progress for XACIATO. However, challenges remain with decreased R&D spending, operational hurdles for Sildefanil Cream, and overall financial losses.Read More>---
DARE Stock 12 Month Forecast
Average Price Target
$12.00
▲(304.04% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
0/20 ratings generated profit
1 Year Average Return
-45.32%
reiterated a buy rating 3 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -45.32% per trade.
---